<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Lonza Group Ag — News on 6ix</title>
    <link>https://6ix.com/company/lonza-group-ag</link>
    <description>Latest news and press releases for Lonza Group Ag on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 11:55:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/lonza-group-ag" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361bcc78dffbe2df13f51c.webp</url>
      <title>Lonza Group Ag</title>
      <link>https://6ix.com/company/lonza-group-ag</link>
    </image>
    <item>
      <title>Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products</title>
      <link>https://6ix.com/company/lonza-group-ag/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products-2</link>
      <guid isPermaLink="true">https://6ix.com/company/lonza-group-ag/news/simulations-plus-announces-collaboration-with-lonza-and-us-fda-to-advance-predictive-frameworks-for-complex-oral-drug-products-2</guid>
      <pubDate>Tue, 21 Apr 2026 11:55:00 GMT</pubDate>
      <description>RESEARCH TRIANGLE PARK, N.C., April 21, 2026--Simulations Plus, Inc. (Nasdaq: SLP) (&quot;Simulations Plus&quot; or the &quot;Company&quot;), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research collaboration with Lonza Group AG (&quot;Lonza&quot;), a leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry, and the U.S. Food and Drug Administration (FDA) to develop and validate a mech</description>
    </item>
    <item>
      <title>Lone Star Funds Announces Agreement to Acquire the Capsules &amp; Health Ingredients Division of Lonza Group AG</title>
      <link>https://6ix.com/company/lonza-group-ag/news/lone-star-funds-announces-agreement-to-acquire-the-capsules-and-health-ingredients-division-of-lonza-group-ag</link>
      <guid isPermaLink="true">https://6ix.com/company/lonza-group-ag/news/lone-star-funds-announces-agreement-to-acquire-the-capsules-and-health-ingredients-division-of-lonza-group-ag</guid>
      <pubDate>Fri, 06 Mar 2026 17:30:00 GMT</pubDate>
      <description>DALLAS &amp; NEW YORK &amp; LONDON &amp; TOKYO, March 06, 2026--Lone Star Funds (&quot;Lone Star&quot;) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules &amp; Health Ingredients (&quot;CHI&quot;) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business.</description>
    </item>
    <item>
      <title>Lonza&apos;s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs</title>
      <link>https://6ix.com/company/lonza-group-ag/news/lonzas-synaffix-sidewinder-therapeutics-announce-083000766</link>
      <guid isPermaLink="true">https://6ix.com/company/lonza-group-ag/news/lonzas-synaffix-sidewinder-therapeutics-announce-083000766</guid>
      <pubDate>Wed, 07 Jan 2026 08:30:00 GMT</pubDate>
      <description>Synaffix B.V. (&quot;Synaffix&quot;), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Sidewinder Therapeutics, a precision ADC therapeutics company with a pipeline of bispecific antibodies with enhanced tumor-cell specificity and internalization, today announced that they have entered into a multi-target licensing agreement to develop first-in-class bispecific ADC</description>
    </item>
    <item>
      <title>Lonza&apos;s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC</title>
      <link>https://6ix.com/company/lonza-group-ag/news/lonzas-synaffix-collaborates-qurient-therapeutics-073000178</link>
      <guid isPermaLink="true">https://6ix.com/company/lonza-group-ag/news/lonzas-synaffix-collaborates-qurient-therapeutics-073000178</guid>
      <pubDate>Thu, 25 Sep 2025 07:30:00 GMT</pubDate>
      <description>Synaffix B.V. (&quot;Synaffix&quot;), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly announced that it has entered into a licensing agreement with Qurient Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, for the development of a dual-payload ADC.</description>
    </item>
  </channel>
</rss>